Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR–mediated DNA Damage Response
Li Ding(Mayo Clinic), Daniel D. Billadeau(Mayo Clinic), Spencer Kiers(Mayo Clinic), John J. Dubé(Université de Sherbrooke), Jin‐San Zhang(Wenzhou Medical University), Debabrata Mukhopadhyay(Jacksonville College), Francis J. Giles(National University of Ireland), Andrey Ugolkov(Fate Therapeutics (United States)), Andrew P. Mazar(Northwestern University), Enfeng Wang(Jacksonville College), Shamit K. Dutta(WinnMed), Daniel M. Schmitt(Fate Therapeutics (United States)), Olga Alekhina(Mayo Clinic), Vijay Sagar Madamsetty(Jacksonville College), Yu Zhang(Mayo Clinic), Alan P. Kozikowski(Chembio (United States))
Cited by 75
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
|Journal for ImmunoTherapy of Cancer|2018|468